-+ 0.00%
-+ 0.00%
-+ 0.00%

Prelude Therapeutics Expects Cash Runway Into Second Quarter of 2028

PUBT·11/16/2026 12:21:10
Listen to the news
Prelude Therapeutics Expects Cash Runway Into Second Quarter of 2028
  • Prelude Therapeutics expects its current cash runway to extend into the second quarter of 2028.
  • Resources are expected to support key data milestones across multiple programs over the next 12-24 months.
  • Initial proof-of-concept data for breast cancer candidate PRT13722 are anticipated in the second half of 2027; Phase 1 enrollment is underway.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prelude Therapeutics Inc. published the original content used to generate this news brief on November 13, 2026, and is solely responsible for the information contained therein.